ALK and lung carcinoma: Furthermore, a previously reported patient with metastatic ALK-rearranged lung cancer harboring an acquired ALK resistance mutation (ALK I1171N) showed a good response to ensartinib, with mild rash, and no further brain metastases after 3 months of follow-up (27).